pillbase.ru

ITVISMA

Active substance: onasemnogene abeparvovec

INJECTION, SUSPENSION · ONASEMNOGENE ABEPARVOVEC 40000000000000 [arb'U]/mL

United StatesActive

Marketing holder: Novartis Innovative Technologies Inc.

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 2
  • Золгенсма®
    раствор для инфузий, 2x10^13 вектор-геномов/мл, 8.3 мл (original in Russian, GRLS)
    ЛП-№(001462)-(РГ-RU)
    Новартис Фарма АГ
  • Золгенсма®
    раствор для инфузий, 2x10^13 вектор-геномов/мл, 8.3 мл (original in Russian, GRLS)
    ЛП-007675
    Новартис Фарма АГ
EU 2
  • Itvisma
    onasemnogene abeparvovec
    EMEA/H/C/006498
    Novartis Europharm Limited
  • Zolgensma
    onasemnogene abeparvovec
    EMEA/H/C/004750
    Novartis Europharm Limited
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-3f7f-71a4-90df-9e29a94a09b4,01a120c5-33e9-76e3-a57e-195cd9461717;count=2 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a12090-d2ca-7941-98e8-ffcc8393791e;count=1 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
71894-200
Registration status
Active
Dispensing
Prescription only
Route
INTRATHECAL
Sources
  • product · openFDA NDC · 71894-200 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 71894-200 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 71894-200 · Verified 2026-10-09 · open in source